Document:

Exhibit 10.30
                                                                   -------------

                                 PROMISSORY NOTE

Principal Amount                                       Sunnyvale, California
EUR 250,000                                                    July 25, 2007

     For value received, the undersigned, Intraop Medical Corporation, a Nevada
corporation, (the "Company") promises to pay to the order of Eckert & Ziegler
Strahlen-und Medizintechnik AG ("Lender"), in lawful money of the United States
of America, the principal sum of Two Hundred Fifty Thousand Euros
((euro)250,000.00), or such lesser principal amount as may be outstanding under
this Note plus simple interest thereon from the date hereof on the aggregate
unpaid principal amount until such amount is paid in full at the annual rate of
7.5%, or the maximum rate allowed by law, whichever is less (calculated on the
basis of a 365 day year). Principal and accrued interest under this Note shall
be due and payable on the earlier of (i) twenty (20) days from the date on which
the Company receives an equity investment in excess of $4,000,000, or (ii)
January 31, 2008 (or such later date as mutually agreed by the parties hereto).
All payments on or in respect of this Note or the indebtedness evidenced hereby
shall be made to Lender without set-off or counterclaim and free and clear of
and without any deductions of any kind.

     1.        Issuance of Warrant. The Company shall issue to Lender, upon
issuance of this Note, a two-year warrant to purchase up to 100,000 shares of
the Company's Common Stock (the "Warrant") at an exercise price of $0.45 per
share.

     2.        Default; Acceleration of Obligation. The Company will be deemed
to be in default under this Note (an "Event of Default") and the outstanding
unpaid principal balance of this Note, together with all interest accrued
thereon, will immediately become due and payable in full, without the need for
any further action on the part of Lender, upon (a) the Company's failure to pay
any principal or any accrued interest under the Note when the same is due and
payable and such failure to pay is not cured by the Company within five (5)
calendar days after Lender gives written notice of such failure to pay to the
Company; (b) upon the filing by or against the Company of any voluntary or
involuntary petition in bankruptcy or any petition for relief under the federal
bankruptcy code or any other state or federal law for the relief of debtors;
provided, however, with respect to an involuntary petition in bankruptcy, such
petition has not been dismissed within thirty (30) days after the filing of such
petition; (c) upon the execution by the Company of an assignment for the benefit
of creditors or the appointment of a receiver, custodian, trustee or similar
party to take possession of the Company's assets or property; or (d) upon any
breach, default or violation by the Company of any other term, condition,
obligation or covenant of this Note that is not cured within thirty (30) days of
receipt of written notice of such breach, default or violation by the Company
from Lender.

     3.        Remedies on Default; Acceleration. Upon any Event of Default,
Lender may declare the entire unpaid principal and accrued interest amount under
this Note to be immediately due and payable in full and may pursue any legal or
equitable remedies that are available to Lender.

                                       1
<PAGE>

     4.        Representations and Warranties of the Company. The Company
represents and warrants to Lender that the Company has all right, power and
authority necessary to make, enter into and perform its obligations under this
Note. This Note is a valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as limited by
applicable bankruptcy, insolvency, moratorium or other laws of general
application relating to or affecting the enforcement of creditors' rights.
Neither the execution and delivery of this Note nor the consummation of any
transaction contemplated hereby has constituted or resulted in, or will
constitute or result in, a breach of the provisions of any instrument, contract
or agreement to which the Company is a party or by which the Company is bound,
or the violation of any law, judgment, decree or governmental or administrative
order, rule or regulation applicable to the Company. No consent of any other
person (including without limitation any stockholder or creditor of the Company)
is required in connection with the execution, delivery, performance, validity or
enforceability of this Note.

     5.        Representations and Warranties of Lender. Lender is acquiring the
Note and the Warrant for its own account as principal, not as a nominee or
agent, for investment purposes only, and not with a view to, or for, resale or
distribution thereof and no other person or entity has a direct or indirect
beneficial interest in such Note. Lender acknowledges that the offering and sale
of the Note and the Warrant (the "Offering') is intended to be exempt from
registration under the Securities Act of 1933, as amended (the "Securities
Act"), by virtue of Section 4(2) of the Securities Act and the provisions of
Regulation D promulgated thereunder ("Regulation D"). In furtherance thereof,
Lender represents and warrants to the Company as follows: (i) Lender does not
have a present interest to distribute or transfer the Note or the Warrant issued
to it or the securities received upon exercise of the Warrant; (ii) Lender has
such knowledge and experience in financial, and business matters as to be
capable of evaluating the merits and risks of an investment in the Note and the
Warrant and (iii) Lender is an "accredited investor," as that term is defined in
Rule 501 of Regulation D.

     6.        Miscellaneous.

               (a)      Transferability.  This Note may be  transferred  or
assigned only with the prior written consent of the Company and only in
compliance with applicable federal and state securities laws. In the event of
such transfer or assignment, Lender shall surrender this Note for registration
of transfer or assignment, duly endorsed, or accompanied by a duly executed
written instrument of transfer or assignment in form satisfactory to the
Company. Thereupon, a new Note for like principal amount and interest will be
issued to, and registered in the name of, the transferee or assignee. Interest
and principal are payable only to the registered holder of the Note.

               (b)      Governing  Law;  Jurisdiction.  This Note  shall be
deemed to be made under and shall be interpreted under the laws of the State of
California (without giving effect to the conflict of law principles thereof).

               (c)      Waiver and Amendment.  Any  provision of this Note may
be amended or modified only by a writing signed by both the Company and Lender.
Except as provided below with respect to waivers by the Company, no waiver or
consent with respect to this Note will be binding or effective unless it is set
forth in writing and signed by the party against whom such waiver is asserted.

                                       2
<PAGE>

No delay or failure on the part of either party in exercising any right or
remedy under this Note will operate as a waiver of such right or any other
right. A waiver given on one occasion will not be construed as a bar to, or as a
waiver of, any right or remedy on any future occasion. The Company hereby waives
presentment, notice of non-payment, notice of dishonor, protest, demand and
diligence.

               (d)      Severability.  If any provision of this Note, or the
application of it to any party or circumstance is held to be invalid, such
provision shall be ineffective, but the remainder of this Note, and the
application of such provision to the other parties or circumstances, shall not
be affected thereby.

               (e)      Notice.  Any  notice  required  or  permitted  under
this Note shall be given in writing and will be deemed effectively given upon
personal delivery; upon confirmed transmission by telecopy or telex; or three
(3) days following deposit with the United States Post Office, by certified or
registered mail, postage prepaid, addressed to the address of the Company or
Lender as set forth below or at such other address as such party may specify by
written notice given in accordance with this Section.

                                       3
<PAGE>

     IT WITNESS WHEREOF, the Company and Lender have executed this Note as of
the day and year first above written.

                             THE COMPANY:

                             INTRAOP MEDICAL CORPORATION
                             A Nevada corporation

                             By: /s/ Donald A. Goer
                                 ------------------
                                 Name:     Donald A. Goer
                                 Title:    President and Chief Executive Officer

                             Address:      570 Del Rey Avenue
                                           Sunnyvale, CA  94085

                             LENDER:

                             ECKERT & ZIEGLER STRAHLEN-UND MEDIZINTECHNIK AG
                             A                    corporation
                               ------------------

                             By:  /s/ Andreas Eckert
                                  ------------------
                                  Name:    Andreas Eckert
                                  Title:

                             Address:      Robert-Rossie-Strasse 10
                                           D-13125 Berlin
                                           Germany

                                       4Exhibit 10.31
                                                                   -------------

                  FINAL SETTLEMENT AGREEMENT AND MUTUAL RELEASE
                  ---------------------------------------------

     This Agreement is made and entered into effective July 2, 2007, between DLA
Piper US LLP ("DLA Piper"), formerly known as DLA Piper Rudnick Gray Cary US
LLP, and Intraop Medical Corporation ("Intraop") (DLP Piper and Intraop
collectively referred to as "the Parties").

                                    RECITALS
                                    --------

     1.        DLA Piper performed securities and corporate legal services to
Intraop of which $455,797 in fees and costs advanced remain unpaid. A dispute
arose between the Parties concerning the amount of attorneys' fees that Intraop
should pay to DLA Piper for the services performed by DLA Piper (the disputes of
the Parties are hereafter referred to as the "Claims"). The Parties now desire
to settle the Claims. In accordance with this desire and in consideration of the
mutual promises made in this Agreement, the Parties agree as follows:

                           OBLIGATIONS OF THE PARTIES
                           --------------------------

     2.        Intraop has agreed to issue to DLA Piper a warrant to purchase
400,000 shares of Intraop common stock and to pay to DLA Piper the total sum of
$228,000 (two hundred and twenty-eight thousand dollars) under the following
schedule: Six equal monthly payments of $38,000 (thirty eight thousand dollars)
each, for six months beginning with a first payment on the execution of this
Agreement and on the fifteenth day of each succeeding month thereafter with
payment in full to occur no later than November 15, 2007.

     3.        On the execution of this Agreement, Intraop shall issue to DLA
Piper a warrant entitling DLA Piper to purchase 400,000 shares of Intraop common
stock with a per share exercise price equal to $.45 per share (the "New
Warrant").

                                       1
<PAGE>

The form of the warrant is attached hereto as Exhibit B and will be executed and
delivered on execution of this Settlement Agreement.

               a.       Intraop will register the New Warrant on the next
registration statement filed with the SEC. The registration of the shares
underlying the New Warrant shall be maintained effective for two years from
their date of issuance.

               b.       DLA Piper will agree to abide by the terms and
conditions of Intraop's current Lock-Up Agreement, a copy of which is attached
hereto, marked Exhibit C, with respect to the New Warrant.

               c.       This Agreement is subject to, with regard to the
issuance of the New Warrant, the approval of all Intraop's senior and
convertible debenture investors.

               d.       Intraop shall immediately cancel the currently
outstanding Warrant #C-37 dated October 27, 2003, to purchase 150,000 shares of
common stock of Intraop Medical, Inc. held by DLA Piper and DLA Piper will
surrender Warrant #37 at the closing for cancellation.

                             MUTUAL GENERAL RELEASE
                             ----------------------

     4.        The performance of the obligations set forth in this Agreement
shall constitute consideration for the release of claims set forth in this
Section.

     5.        Except with respect to the obligations set forth in this
Agreement, the Parties shall, for themselves and their respective legal
successors and assigns release and forever discharge each other and their
respective shareholders, partners, directors, officers, employees, agents,
attorneys, legal successors and assigns of and from any and all claims, demands,
damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses,
liens, actions and causes of action of every kind and nature whether now known
or unknown, suspected or unsuspected, which either now has, owns or holds or at
any time before ever owned or held or could, shall or may in the future have,
own or hold against the other based upon or arising out of any matter, cause,
fact, thing, act, omission or any of the Claims occurring or existing at any
time up to and including the effective date of this Agreement (collectively the
"Released Matters").

                                       2
<PAGE>

     6.        It is the intention of the Parties in executing this Agreement
and in paying and receiving the consideration set forth in this Agreement that
this Agreement shall be effective as a full and final accord and satisfaction
and mutual general release of and from all Released Matters.

     7.        In furtherance of the intentions set forth in this Agreement each
of the Parties acknowledges that it is familiar with California Civil Code
Section 1542 which provides as follows:

     GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW
     OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE
     RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR
     HER SETTLEMENT WITH THE DEBTOR.

     Each of the Parties waives and relinquishes any rights or benefits which it
has or may have under Section 1542 or any similar provision of the law of any
other jurisdiction to the full extent that it may lawfully waive its rights and
benefits pertaining to the Released Matters. In connection with this waiver and
relinquishment, each of the Parties acknowledges that it is aware that it or its
attorneys or accountants may later discover claims or facts in addition to or
different from those which it now knows or believes to exist with respect to the
subject matter of this Agreement or the other Parties to this Agreement but that
it is its intention hereby fully, finally and forever to settle and release all
of the Released Matters. In furtherance of this intention, the releases given in
this Agreement shall be and remain in effect as full and complete mutual
releases as to the Released Matters despite the discovery or existence of any
such additional or different claims or facts.

     8.        The Parties acknowledge that they each deny any wrongdoing
whatsoever in connection with one another and that the settlement agreement made
pursuant to this Agreement is made solely for the purpose of compromising
disputed claims and avoiding the time, expense and uncertainty of litigation.

                                       3
<PAGE>

It is expressly understood and agreed that nothing contained in this Agreement
shall constitute or be treated as an admission of any wrongdoing or liability on
the part of any of the Parties hereto.

     9.        The Parties each warrant and represent to the other that they are
the sole and lawful owners of all rights, title and interest in and to all of
the respective Released Matters and that they have not voluntarily, by operation
of law or otherwise assigned or transferred or purported to assign or transfer
to any person any portion of any Released Matter or any claim, demand, or right
against the other Parties. The Parties further warrant and represent that the
individuals signing this Agreement on behalf of the Parties has full authority
to do so and to bind the Parties to the terms of this Agreement.

     10.       The Parties agree that for purposes of enforcement in court or
any legal proceeding, or as an affirmative defense, this Agreement may be
disclosed and admitted into evidence despite the provisions concerning mediation
confidentiality.

     11.       Any dispute arising out of this Agreement shall be submitted to
the Honorable Edward A. Infante at ADR Services for binding resolution.

                                  BENEFICIARIES
                                  -------------

     12.       This Agreement is not for the benefit of any person who is not a
signatory to this Agreement or specifically named a beneficiary in this
paragraph. The provisions of this Agreement and the release contained in this
Agreement shall extend to and inure to the benefit of and be binding upon, in
addition to the Parties, just as if they had executed this Agreement: the
respective legal successors and assigns of each of the Parties, each and every
entity which now is or ever was a division, parent or subsidiary, and their
respective legal successors and assigns, the respective past and present
shareholders, partners, officers, directors, agents, employees and attorneys of
the Parties, and each of them.

                                       4
<PAGE>

                                     GENERAL
                                     -------

     13.       Each party acknowledges to the other Parties that it has been
advised by independent legal counsel of its own choice throughout all of the
negotiations (or had and declined the opportunity to do so) which preceded the
execution of this Agreement and that it has executed this Agreement with the
consent and on the advice of its independent legal counsel. Each party further
acknowledges that it and its counsel have had adequate opportunity to make
whatever investigation or inquiry they may deem necessary or desirable in
connection with the subject matter of this Agreement prior to its execution and
delivery and acceptance of the consideration specified in this Agreement.

     14.       This Agreement and any other documents referred to in this
Agreement shall be interpreted, enforced and governed under the laws of
California. Any action to enforce this Agreement shall be venued in the Superior
Court of California, County of San Francisco. Counsel for all Parties have read
and approved the language of this Agreement. The language of this Agreement
shall be construed as a whole according to its fair meaning, and not strictly
for or against any of the Parties.

     15.       The titles of the various articles of this Agreement are used for
convenience of reference only and are not intended to and shall not in any way
enlarge or diminish the rights or obligations of the Parties or affect the
meaning or construction of this Agreement.

     16.       This Agreement, in all respects, shall be interpreted, enforced
and governed by and under the laws of the State of California.

     17.       A breach of any representation or warranty in this Agreement is
material and shall be deemed a breach of this Agreement.

                                       5
<PAGE>

     18.       It is expressly understood and agreed by the Parties that this
Agreement and all of its terms shall be binding upon each Party's
representatives, heirs, executors, administrators, successors and assigns.

     19.       The Parties agree that this Agreement shall be construed without
regard to the drafter of the same and shall be construed as though each party to
this Agreement participated equally in the preparation and drafting of this
Agreement.

     20.       If any party to this Agreement asserts a claim for breach of this
Agreement or seeks to enforce its terms, the prevailing party in any such
proceeding shall be entitled to recover costs and reasonable attorneys' fees.

     21.       The Parties agree to execute such other documents as reasonably
may be required to effectuate this Agreement.

     22.       Should a court of government agency invalidate any of the
provisions of this Agreement, the remaining provisions will stay in effect.

     23.       This Agreement may be executed in counterparts which, taken
together, shall constitute one and the same agreement as through they had been
executed together and shall be effective as of the date set forth on page 1.

     24.       The individuals signing this Agreement hereby warrant and
represent that, except as otherwise set forth herein, and specifically as set
forth in paragraph 3(c), above, they have the authority to enter into this
agreement on behalf of the respective parties hereto.

     25.       This Agreement constitutes the Final Agreement as defined by the
Parties in the Agreement. Except for as set forth herein, this Agreement may not
be altered or amended except in a writing signed by all of the Parties to this
Agreement. Neither this Agreement nor any of the obligations created under this
Agreement shall be construed as an admission of any party to this Agreement of
any liability of any kind to the other Parties.

                                       6
<PAGE>

Each party expressly denies that it is in any way liable or indebted to the
other Parties except as set forth in this Agreement.

DLA Piper US LLP                           Intraop Medical Corporation

BY:  /s/ Gilles S. Attia                   BY: /s/ Donald A. Goer
     -------------------                       ------------------
Name:   Gilles S. Attia                    Name:    Donald A. Goer, Ph.D.
Title:  Partner                            Title:   President and Chief
                                                    Executive Officer

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]